The company is involved in developing and manufacturing nasal and pulmonary drug delivery devices. In 2000 Pardonge served as R&D manager for Aptar Pharma’s prescription division and promoted
The patients in single arm open label extension study were given autologous stem cell transplant along with modified T cells. The clinical trial, which enrolled 6 patients, aimed
The Good Laboratory Practice compliant facility received all statutory approvals from the Atomic Energy Review Board of India to conduct 3H and 14C synthesis. GVK BIO CEO Manni
Exjade is used to treat chronic iron overload requiring chelation therapy when deferoxamine therapy is insufficient in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndromes.
Orexo, which expects the Zubsolv approval in July 2013, schedules the launch for September 2013. Orexo president and CEO Anders Lundstrom said, "We have a good chance of
The swab will quantitatively measure the fetal fibronectin (fFN), a protein, which will help finding out whether a woman is likely to give birth prematurely or not. The
The CHMP opinion indicates the use of the broad coverage vaccine in individuals older than two months. Novartis vaccines and diagnostics division head Andrin Oswald said Bexsero represents
The new solution has a consumer and sponsor component, which will offer pharmaceutical companies and CROs a better return on recruitment investment. PatientLive also provides patients with more
The double-blind, placebo-controlled, randomized study was designed to evaluate the safety and efficacy of 165mg and 330mg doses of pregabalin as an adjunctive therapy for epilepsy patients with
NIH will leverage the technology in gathering, investigation, archiving and switching over of scientific data that is useful for researchers working on immunology and immune-mediated diseases. Northrop Grumman
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.